Summary
Read original article →
The Trump administration is preparing 200% tariffs on generic pharmaceuticals as part of its broadening trade actions, raising concerns across healthcare supply chains. The proposal adds to a deluge of sector-specific and country-based tariffs rolled out in the president's second term.